Evaxion develops method to enhance ai drug development with deep probabilistic programming

Copenhagen, denmark, june 25, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the acceptance of a new scientific paper by the international conference on machine learning ( icml 2021 ). a draft of the article is available on the open-access scientific server biorxiv.org .
EVAX Ratings Summary
EVAX Quant Ranking